Emerging Perspectives of Bone Metastasis in Hepatocellular Carcinoma

Xiaofeng Yuan††, Ming Zhuang††, Xi Zhu†,2†, Dong Cheng†, Jie Liu†, Donglin Sun†, Xubin Qiu†*, Yunjie Lu†* and Kurt Sartorius3,4,5*

1 The Third Affiliated Hospital of Soochow University, Changzhou, China, 2 Department of Infectious Diseases, The First Peoples’ Hospital of Kunshan, Kunshan, China, 3 Hepatitis Diversity Research Unit, School of Internal Medicine, University of the Witwatersrand, Johannesburg, South Africa, 4 Africa Hepatopancreatobiliary Cancer Consortium (AHPBCC), Mayo Clinic, Jacksonville, FL, United States, 5 School of Laboratory Medicine and Molecular Sciences, College of Health Science, University of KwaZulu-Natal, Durban, South Africa

Recent evidence suggests the global incidence and mortality of hepatocellular carcinoma (HCC) are increasing. Although the highest incidence of HCC remains entrenched in WHO regions with high levels of HBV-HCV infection, the etiology of this disease is rapidly changing to include other lifestyle risk factors. Extrahepatic metastasis is a frequent feature of advanced HCC and most commonly locates in the lungs and bone. Bone metastasis in HCC (HCC-BM) signals a more aggressive stage of disease and a poorer prognosis, simultaneously HCC-BM compromises the function and integrity of bone tissue. HCC induced osteolysis is a prominent feature of metastasis that complicates treatment needed for pathologic fractures, bone pain and other skeletal events like hypercalcemia and nerve compression. Early detection of bone metastases facilitates the treatment strategy for avoiding and relieving complications. Although recent therapeutic advances in HCC like targeting agents and immunotherapy have improved survival, the prognosis for patients with HCC-BM remains problematic. The identification of critical HCC-BM pathways in the bone microenvironment could provide important insights to guide future detection and therapy. This review presents an overview of the clinical development of bone metastases in HCC, identifying key clinical features and identifying potential molecular targets that can be deployed as diagnostic tools or therapeutic agents.

Keywords: hepatocellular carcinoma (HCC), bone metastasis, biomarkers, osteolysis, bone remodeling

BACKGROUND OF BONE METASTASIS IN HCC

A recent analysis of the Globocan 2020 results indicates that the highest incidence of liver cancer persists in East Asia (17.8), North Africa (15.2), Micronesia (14.6), South East Asia (13.6) and Micronesia (11.4) against a global ASR of 9.5 (1). Hepatocellular carcinoma makes up > 75% of all primary liver cancer incidence (2, 3) and accounts for the fourth highest number of cancer-related death in the entire world (4). The incidence and etiology of HCC differ markedly across the WHO regions. In regions like Eastern Asia and Sub-Saharan Africa, for example, where HBV infection is
endemic, the etiology of disease is significantly different from risk factors like NASH and NAFLD that predominate in Western countries. Early detection of HCC is also more likely in developed countries and patients in developing countries often only present at advanced stage disease (5, 6). Early diagnosis or screening for HCC is crucial and eliminating risk factors like viral infection (HBV/HCV), alcohol, dietary toxins, tobacco, aflatoxins and aristolochic acid is likely to reduce incidence more than current clinical treatment options. Due to progress in diagnostics of HCC such as CT/MRI, PET-CT and bone scintigraphy (BS), during the past 20 years, overall survival rates for HCC patients have improved (7–9). Nevertheless, extrahepatic metastases have become more common in recent years and most HCC patients are only diagnosed at an advanced stage. About 16.1% to 38.5% of HCC patients exhibit bone metastasis (BM) at first diagnosis, and 11.7% develop BM following curative resections (10). Patients with HCC who have developed bone metastasis (HCC-BM) have a poor prognosis and a median survival time of only 4.6 months. Risk factors contributing to poor survival among HCC-BM patients include Child-Pugh class A group, alpha-fetoprotein (AFP) levels (> 30 ng/mL), and tumor size (> 5 cm) (11). Moreover, the majority of HCC-BM patients suffer from skeletal-related events (SREs), including fractures and spinal cord compression caused by pathological conditions. Symptoms of these SREs include severe pain and neurological deficits that drastically deteriorate the patients’ quality of life. Sadly, there is no definitive therapeutic strategy for the management of HCC-BM. There are contrasting findings about the extent of HCC-BM and some studies indicate it is an infrequent form of presentation (10, 12) whereas others suggest it is relatively common and occurs in ~33.3% of patients with HCC (13). HCC cases reported with bone metastasis tend to have multiple metastatic spreads elsewhere as well (14).

In most cases, bone metastases from HCC are irreversible and incurable, as well as associated with pathological fractures, severe pain, decreased quality of life and poor prognosis (15). Bone metastases increase the burden on healthcare providers and individuals due to switching the medical paradigm from cure to palliation. As a result of advancements in the treatment of HCC-BM patients, it has become possible to identify which patients benefit the most from the treatments available (16). On a more encouraging note, the combined strategies of locoregional therapies and/or systemic therapy are constantly being evaluated. This review paper specially describes HCC-BM pathogenesis and identifies key biomarkers and potential therapeutic agents that could potentially be employed for the early diagnosis and/or treatment.

**METASTATIC DISSEMINATION IN HCC**

HCC pathogenesis occurs in a setting of chronic inflammation, fibrogenesis and liver damage against a background of frequent immune reactions, uncontrolled hepatocyte proliferation and the frequent mutations of proto-oncogenes and tumor suppressor genes (2). Typically, a key step in HCC metastasis is the loss of regulatory controls in cellular replication and metastasis occurs in conditions of chromosomal instability that can cause a leakage of tumor cell DNA that spread to distant organs (17). When primary HCC proliferates locally, epithelial-mesenchymal transformation (EMT) is activated by widespread epigenetic reprogramming of gene expression, and epithelial cells lose their cell polarity and adhesion properties, becoming more migratory and invasive (18). Once cell polarity transition occurs, polarized epithelial cells lose intercellular croslinking and acquire a spindle-like morphology thus facilitating migration to distant organs (19). Simultaneously neo-angiogenesis is stimulated to deliver oxygen, nutrients, and growth factors to facilitate tumor growth and enable invasion (20). Vascular endothelial growth factor (VEGF), known as a crucial factor driving angiogenesis in the primary HCC lesion and its metastasis to bone, plays a critical role in stimulating bone resorption and facilitating tumor growth in bone (21).

**Macro-and Microinvasion in HCC-BM**

A small proportion of cancer cells in a primary HCC tumor have the metastatic potential to disseminate and distribute from the blood and/or lymphatic systems to distant tissues or organs (22) (See Figure 1). Various studies have demonstrated that both macro- and microvascular invasion are universally recognized as a predictor of distant metastasis for HCC (23, 24). The presence of tumor cells in the hepatic portal vein can contribute to intrahepatic metastasis, while they can also appear in the hepatic vein to induce the occurrence of distant metastasis of HCC and recurrence after liver transplantation. Clinicopathological features of HCC with portal hypertension account for the predilection of metastases to the spine throughout the valve-less venous plexus (25).

In recent years, the rapid development of radionics and artificial intelligence has made it easy to detect micro-vascular invasion (MVI) by analyzing the peritumoral area. This technology has unique diagnostic advantages and can guide HCC treatment selection and prognosis evaluation (24). Currently, the use of this technology for MVI detection is limited by the radiologists’ subjective judgment and lack of uniform guidelines. This method, however, is a promising way to determine the degree of HCC progression using simple imaging data before surgery. Cancer cells can also be found in neuronal spaces as well as the vascular and lymphatic systems, and the process of migration along nerves is termed perineural invasion (PNI) (26). After vascular invasion, metastatic cancer cells in the blood or lymph nodes are called circulating tumor cells (CTCs) and the presence of positive CTCs or ctDNA in HCC indicates a more aggressive phenotype and poorer prognosis (27, 28). Detection of CTCs and circulating tumor DNA (ctDNA) using the new emerging methodologies of liquid biopsy or lymph node biopsy is currently an important method for the diagnosis of metastatic cancers (29, 30).

**Preconditions for HCC-BM Establishment**

The transport of cancer cells via blood vessels and lymph nodes, disseminates them from the primary tumor to bone marrow for further progression to bone metastasis (31). The CTCs enter the
bone marrow compartment by crossing the endothelial cell barrier as well as the basement membrane of blood vessels, and engage in specialized microenvironments or 'bone niche'. A few of these disseminated tumor cells (DTCs) survive to grow in the bone marrow after extravasating into the metastatic site (32). They can either exist as individual cells in a quiescent state or form small masses that do not expand. Besides the invasive qualities, they need to have the ability to adapt to the microenvironment in ways that encourage colonization (32). Often, DTCs that colonize bone and evade the immune system typically remain dormant for long periods. Cellular dormancy, moreover, is a profound mechanism that helps tumor cells evade immune surveillance and evolve to develop chemoresistance (33, 34).

The molecular mechanisms including extracellular matrix (ECM) development, metabolic and epigenetic changes, stemness, dysregulated non-coding RNAs, as well as the activation of the p38 stress-induced pathway, can mobilize dormant cancer cells to progress to form a micro-metastasis (35). As the metastasis progresses, the reactivated dormant cells proliferate uncontrollably and eventually begin to modify bone structure. Clinical speculation also indicates that these tumor cells are at their most vulnerable state in this transition stage for therapeutic targeting (36). Fortunately, technology has made it possible to study rare cells in bone, including dormant cells to complement our understanding of these early steps in BM development (36). Although the general progress of bone metastasis from different soft cancers is similar, however, the thorough and exact pathophysiology underlying the crucial early events of HCC-BM is not yet fully understood. Further research is necessary to elucidate the precise mechanism of DTCs in the bone and determine the optimum conditions for dormancy-break, or - eradication.

**HCC-BM BIOMARKERS**

According to various studies, HCC metastases and prognosis can be determined by reproducible gene expression patterns in the liver microenvironment (37, 38). Gene-expression profiles that strongly predict metastasis and poor outcome may already be present in primary tumors (see Figure 2). Potential biomarkers in serum, urine, and tumor tissue, that have been identified in a
range of clinical studies to predict HCC-BM, as well as determine prognosis in HCC patients (see Table 1).

In HCC, the molecular pathogenesis is extremely complex and heterogeneous, and the process of metastatic dissemination from HCC can be generally separated into the sequential steps: primary tumor growth, cell polarity transition, seed, dormancy, and secondary outgrowth (47, 48). Each step cannot be missed, which means that the process of metastasis is time-consuming and complicated. Given the vulnerability of the metastatic process discussed above, a number of target-oriented HCC-BM biomarkers have been identified (see Figure 1/Table 1).

In primary HCCs, CXC chemokine receptor 4 (CXCR4) expression may be a biomarker for BM that is associated with poor clinical outcome (39). Stromal cell-derived factor-1 (SDF-1), also known as chemokine ligand 12 (CXCL12), can induce metastases through interacting with CXCR4. Interestingly, an elevated CXCR4 level alone does not necessarily result in HCC-BM due to the loss of SDF-1 expression (49). In another study, the expression of seven serum peptides sourced from AFP, prothrombin, fibrinogen beta chains, serglycin, transthyretin, isoform 2 of inter-alpha-trypsin inhibitor heavy chain H4 (ITIH4), and isoform 1 of autophagy-related protein 16-2 (ATG-16.2) were used as a collective predictive tool for HCC-BM detection (41). FRZB expression was also up-regulated in HCC-BM suggesting that FRZB might play a key predictor of HCC-BM (42). Neuronal cell bodies and axons of peripheral and central nervous systems express PGP9.5, which is a ubiquitin-protein hydrolase could also be considered as a BM biomarker. Interestingly, one study revealed that PGP 9.5 had a higher nerve density in bone metastases tissues compared with HCC tissues (26). The dysregulated expression of miR-34a as a serum and intra-tumoral tissue biomarker was also found to be a useful predictor for the risk of BM in HCC patients (43), as well as the elevated expression of Inc34a expression (45). In another serum based test, low baseline NTX levels could be correlated with a better outcome in HCC-BM patients with Child–Pugh grade A (44) and finally, serum HGB, ALP and PLT could also be useful predictors of BM-HCC versus HCC (46).

**Bone Remodeling and Bone Destruction**

There is a balance between the resorption of mineralized bone by bone-resorbing cells (osteoclasts, OCs) and the formation of new bone by bone-forming cells (osteoblasts, OBs), which is essential for maintaining bone mass in humans (50). The process of bone remodeling is closely influenced by both systemic and local factors to maintain this physiological balance. Once bone metastasis initiation is activated by homotypic and heterotypic
cellular interactions between cancer cells, OBs and OCs, normal bone homeostasis is easily broken and can lead to a negative chain reaction. Usually, osteolytic and osteogenic metastasis are two opposite types of cancer-related bone metastases (51). The classification is decided by which cell type exerts a dominant effect and represents two extremes of the dysregulation of bone homeostasis, which are bone lysis or sclerosis. Bone metastases in HCC are predominantly osteolytic in nature, and osteoblastic or mixed osteoblastic-osteolytic lesions are possible (21, 52). The main manifestations of osteolytic metastasis are an increased likelihood of systematic severe osteolytic bone lesions and SREs, resulting in fracture, nerve compression syndromes, and even paralysis (53–55). It is worth mentioning that, besides OBs and OCs, the bone microenvironment also consists of stromal cells, hematopoietic cells, and others. However, there is limited recent research reported on these important cells in the evolution of HCC-BM.

**MOLECULAR PATHWAYS OF BONE REMODELING**

As a key regulator of bone homeostasis, receptor activator of nuclear factor-kB (NF-kB) ligand (RANKL) is also referred to as osteoprotegerin ligand (OPGL), osteoclast differentiation factor (ODF), and TNF-related activation-induced cytokine (TRANCE). Various studies indicate that multinucleated osteoclasts originate from monocyte-/macrophage-lineage cells and resorb mineralized bone matrix by creating a microenvironment. Osteoclast precursors overexpress RANK when exposed to macrophage colony-stimulating factor (M-CSF), which binds to RANKL expressed by osteoblasts (56). Through the PI3K/Akt/mTOR and NF-kB pathway, the complex of RANK/RANKL recruits TNF receptor-associated factors (TRAF6), and finally induces osteoclast maturation (57, 58). In contrast, OPG, a soluble RANKL decoy receptor, could block its interaction with RANK by binding RANKL (59). The relative expression levels of RANKL and OPG determine the activation of osteoclasts and bone metabolism.

The normal bone microenvironment consists of osteoblasts, osteoclasts, stromal cells, mineralized bone matrix, hematopoietic cells, and others. But in the presence of metastatic HCC cells, its molecular interactions with the bone microenvironment disrupt the balance of bone metabolism and further drive skeletal metastases. Previous studies (60) have shown that metastatic tumor cells in many cancers including those of the breast, prostate and lung, could directly secret
RANKL or induce osteoblasts to produce RANKL, thereby causing bone destruction and bone formation which is characterized by matrix degradation and release of numerous cytokines and growth factors. Sasaki et al. (61) firstly studied RANKL produced by HCC cells and showed that RANKL activated and differentiated osteoclast precursors, which resulted in osteolysis and bone metastasis. Parathyroid hormone-related protein (PTHrP), an important prognostic factor of malignancy-associated hypercalcemia (MAH), was known to increase the RANKL expression and repress the OPG expression, indicating that PTHrP could promote bone metastasis in breast cancer (62–64). Previous studies have shown that a similar expression trend of PTHrP is undetectable in HCC cells by immunohistochemistry (65). On the other hand, recent clinical studies addressing PTHrP-mediated hypercalcemia have demonstrated that PTHrP can be detected in HCC patients from Australia and Korea (66, 67). Despite the important role of PTHrP in calcium/phosphorus metabolism and bone resorption, there has been no previous evidence of a link between PTHrP expression and bone metastasis in HCC, unlike in other cancers.

### POSSIBLE HCC-BM THERAPEUTIC PATHWAYS

Due to the absence of obvious symptoms in the early onset of bone metastases, the diagnosis of bone metastases is difficult, and an effective treatment has not yet been established. The presence of multiple levels of intratumor heterogeneity is recognized as a distinct characteristic of human tumors that modulates the efficacy of targeted therapy in HCC-BM (see Table 2). Based on next-generation sequencing (NGS), however, important driver of mutations in HCC cells have been determined including EGFR, ALK, KRAS, and PI3KCA (72).

The secreted multifunctional glycoprotein LGALS3 (Lectin galactoside-binding soluble 3) is generally upregulated in tumors through various intracellular and extracellular mechanisms (73). LGALS3 produced by HCC is located on the outer surface of osteoclast progenitor cells (OPs) and promotes CD98- and integrin αvβ3 complex–mediated fusion and podosome formation of osteoclasts. This is explained by increased the formation of TRAP+-multinuclear OCs and TRAP activity, but no alteration of ALP+-OBs along with the interface of bone-tumor (68).

Furthermore, E3 ligase RNF219-mediated α-catenin degradation promotes the overexpression of LGALS3 through YAP1/β-catenin-dependent epigenetic modifications, resulting in HCC-BM and following SREs. A potential therapeutic option, namely, Verteporfin (VP), a YAP specific inhibitor, can block RNF219/α-catenin/LGALS3 axis to effectively inhibit HCC-BM (74). Other studies have focused on the role of long non-coding transcripts in HCC-BM. Long noncoding RNAs (lncRNAs) are RNAs with limited or no coding potential that are longer than two hundred nucleotides in size (75). Emerging evidences indicated that dysregulated lncRNAs lead significantly to the initiation and progression of tumorigenesis (76). Targeting dysregulated lncRNA in HCC-BM pathways, thus, offers another therapeutic option. It has been suggested that the expression of lncZEB1-AS1, an oncogenic lncRNA, is evident in HCC patients with lung (77) and bone metastasis (70). Zinc finger E-box binding homeobox 1 (ZEB1) is also a pivotal regulator that induces EMT and metastasis. LncZEB1-AS1, however, also influences matrix metalloproteinases (MMPs) without EMT-related markers including Vimentin, N-cadherin, or E-cadherin (70). Furthermore, LncZEB1-AS1 serves as a ceRNA for miR-302b and thereby promotes tumor progression via EGFR-PI3K-AKT signaling although no clear evidence about the effect of lncZEB1-AS1 on HCC-BM has been directly demonstrated (70). Lnc34a expression in serum is a potential predictive biomarker for HCC-BM patients (45). Previous series studies indicated that Lnc34a epigenetically inhibits miR-34a expression through recruiting DNMT3a via PHB2 to methylate miR-34a promoter, as well as HDAC1 to promote histones deacetylation. Alternatively, miR-34a also targets Smad4 through the TGF-β pathway and then alters transcription of downstream genes related with BM, for instance, CTGF and IL-11 (71).

### SUMMARY

HCC metastasizes into bone tissue after a cascade of short-term responses. Genetic factors, the tumor microenvironment (TME),

---

**TABLE 2 | Recent advances in molecular mechanisms and oncogenes in HCC-BM.**

| Target       | Clinical association                                      | Location                        | Main mechanism                                                                 | Blocking method                        | Refs |
|--------------|-----------------------------------------------------------|---------------------------------|--------------------------------------------------------------------------------|----------------------------------------|------|
| LGALS3       | LGALS3 overexpression promotes HCC bone metastasis        | The outermost covering of OP cells | Promoting differentiation and Activation of Osteoclasts by activating CD98- and integrin αvβ3 complex–mediated fusion and podosome formation | LGALS3 neutralizing antibody or YAP inhibitor verteporfin P38 inhibitor | (69) |
| H19          | H19 overexpression promotes HCC bone metastasis          | Chromosome 11p15.5              | Reducing OPG expression via PPP1CA-induced P38 dephosphorylation process and promoting ZEB1-dependent EMT by downregulating miR-200b-3p | P38 inhibitor                           | (69) |
| LncZEB1-AS1  | LncZEB1-AS1 overexpression promotes HCC bone metastasis  | Chromosome 10p11.22 region contiguous with ZEB1 | Inducing MMP2, MMP7 and MMP9 upregulation via inhibiting miR-302b, resulting in enhanced EGFR/PI3K-AKT signaling | Compounds targeting the LncZEB1-AS1-miR-302b-EGFR axis Increasing miR-34a or decreasing Smad4 | (70) |
| Lnc34a       | Lnc34a overexpression promotes HCC bone metastasis       | Enriching in colon cancer stem cells (CSCs) | Recruiting Dnmt3a via PHB2 and HDAC1 to methylate and deacetylate the miR-34a promoter and thereby targeting Smad4 via the TGF-β pathway |                                          | (71) |
and other factors all work in concert to promote HCC-BM. Developments in diagnostic technologies, however, allow us to detect HCC-BM in earlier stages using multiple novel technologies, including medical image analysis which is based on artificial intelligence (AI), as well as the use of liquid biopsies and next-generation sequencing (NGS). The accurate detection of HCC-BM stage and its molecular features also promote a clearer picture for patient treatment and prognosis. Currently, traditional treatments such as surgery, radiotherapy and chemotherapy, as well as targeted therapy including sorafenib and bisphosphonate, remain complicated by the complex nature of HCC-BM. However, future research that promotes a better understanding of the intra-tumoral heterogeneity of HCC-BM can improve the development of improved therapy. Understanding the key to heterogeneity will help us develop individualized approaches for HCC patients and new generation drugs can be adjusted accordingly. Alternatively, this understanding can promote the better deployment of current drug alternatives at different stages of HCC-BM pathogenesis. However, our understanding of the molecular etiology of the HCC-BM tumor microenvironment needs to be improved by further studies covering energy metabolism and differential immune responses. In summary, we have offered some further studies covering energy metabolism and differential immune responses. In summary, we have offered some

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article-supplementary material. Further inquiries can be directed to the corresponding authors.

**AUTHOR CONTRIBUTIONS**

XY, MZ, and XZ reviewed the literature and wrote the manuscript. DC, JL, and DS revised the manuscript. XQ, YL, and KS reviewed, revised the manuscript and performed figures and tables of the manuscript. All authors contributed to read and approved the submitted version.

**FUNDING**

This work was supported by the National Natural Science Foundation of China (81971504), Post-Doctoral Special Foundation of China (2020M670065ZX), Post-Doctoral Foundation of Jiangsu Province (2020Z211), Changzhou Society Development Funding (CE20205038), The lifting Project of 2021 Young Scientific and technological talents in Changzhou, Youth Science and Technology Talent Program of Changzhou Health and Family Planning Commission (QN202106 and QN202007), Changzhou SciTech Program (CJ20210085), and Youth Talent Development Plan of Changzhou Health Commission (CZQM2020047).

**REFERENCES**

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jamal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA: Cancer J Clin* (2021) 71(3):209–49. doi: 10.3322/caac.21660
2. El-Serag HB, Rudolph KL. Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis. *Gastroenterology* (2007) 132(7):2557–76. doi: 10.1053/j.gastro.2007.04.061
3. Petrick JL, Florio AA, Znaor A, Ruggieri D, Laversanne M, Alvarez CS, et al. International Trends in Hepatocellular Carcinoma Incidence, 1978–2012. *Int J Cancer*. (2020) 147(2):317–30. doi: 10.1002/ijc.32723
4. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin* (2018) 68(6):394–424. doi: 10.3322/caac.21492
5. Zeng H, Chen W, Zheng R, Zhang S, Ji JS, Zou X, et al. Changing Cancer Survival in China During 2003–15: A Pooled Analysis of 17 Population-Based Cancer Registries. *Lancet Glob Health* (2018) 6(5):e555–e67. doi: 10.1016/S2214-109X(18)30127-X
6. El-Serag HB. Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma. *Gastroenterology* (2012) 142(6):1264–73.e1. doi: 10.1053/j.gastro.2011.12.061
7. Seo HJ, Kim GM, Kim JH, Kang WJ, Choi HJ. (1)(8)-FDG PET/CT in Hepatocellular Carcinoma: Detection of Bone Metastasis and Prediction of Prognosis. *Nucl Med Commun* (2015) 36(3):226–33. doi: 10.1097/MNM.0000000000000246
8. Kim S, Chun M, Wang H, Cho S, Oh YT, Kang SH, et al. Bone Metastasis From Primary Hepatocellular Carcinoma: Characteristics of Soft Tissue Formation. *Cancer Res Treat* (2007) 39(3):104–8. doi: 10.4143/crt.2007.39.3.104
9. Kutaiba N, Ardalan Z, Patwala K, Lau E, Goodwin M, Gow P. Value of Bone Scans in Work-Up of Patients With Hepatocellular Carcinoma for Liver Transplant. *Transplant Direct*. (2018) 4(12):e408. doi: 10.1097/TXD.0000000000000446
10. Natsuiaka M, Omura T, Akaife T, Kuhata Y, Yamasaki K, Sato T, et al. Clinical Features of Hepatocellular Carcinoma With Extrahepatic Metastases. *J Gastroenterol Hepatol* (2005) 20(11):1781–7. doi: 10.1111/j.1440-1746.2005.03919.x
11. Kim S, Choi Y, Kwak DW, Lee HS, Hur WJ, Baek YH, et al. Prognostic Factors in Hepatocellular Carcinoma Patients With Bone Metastases. *Radiat Oncol J* (2019) 37(3):207–14. doi: 10.3857/roj.2019.00136
12. Fujitomi M, Yokota M, Chuman H, Harada H, Zaitai Y, Funakoshi A, et al. Increased Incidence of Bone Metastases in Hepatocellular Carcinoma. *Eur J Gastroenterol Hepatol* (2001) 13(9):1083–8. doi: 10.1097/00004273-200109000-00015
13. Harding JJ, Abu-Nezah G, Chou JF, Owen DH, Ly M, Lowey MA, et al. Frequency, Morbidity, and Mortality of Bone Metastases in Advanced Hepatocellular Carcinoma. *J Natl Compr Canc Netw* (2018) 16(1):50–8. doi: 10.6004/jnccn.2017.7024
14. Buhari S, Ward K, Styler M. Hepatocellular Carcinoma: First Manifestation as Solitary Humeral Bone Metastasis. *Case Rep Oncol Med* (2020) 2020:8254236. doi: 10.1155/2020/8254236
15. Longo V, Brunetti O, D’Oronozo S, Ostuni C, Gatti P, Silvestris F. Bone Metastases in Hepatocellular Carcinoma: An Emerging Issue. *Cancer Metastasis Rev* (2014) 33(1):333–42. doi: 10.1007/s10555-013-9454-4
16. Chen C, Wang G. Mechanisms of Hepatocellular Carcinoma and Challenges and Opportunities for Molecular Targeted Therapy. *World J Hepatol* (2015) 7(15):1964–70. doi: 10.4292/wjh.v7.i15.1964
17. Bakhoun SF, Ngo B, Laughney AM, Cavallo J-A, Murphy CJ, Ly P, et al. Chromosomal Instability Drives Metastasis Through a Cytosolic

DNA Response. *Nature* (2018) 553(7689):467–72. doi: 10.1038/s41586-018-02532

18. Lin J, Lin W, Ye Y, Wang L, Chen X, Zang S, et al. Kindlin-2 Promotes Hepatocellular Carcinoma Invasion and Metastasis by Increasing Wnt/beta-Catenin Signaling. *J Exp Clin Cancer Res* (2017) 36(1):134. doi: 10.1186/s13046-017-0603-4

19. Dongre A, Weinberg RA. New Insights Into the Mechanisms of Epithelial-Mesenchymal Transition and Implications for Cancer. *Nat Rev Mol Cell Biol* (2019) 20(2):69–84. doi: 10.1038/s41580-018-0084-0

20. Bergers G, Hanahan D. Modes of Resistance to Anti-Angiogenic Therapy. *Nat Rev Cancer* (2008) 8(8):592–603. doi: 10.1038/nrc2442

21. Iguchi H, Yokota M, Fukutomi M, Uchimura K, Yonemasu H, Hachitanda Y, et al. A Possible Role of VEGF in Osteolytic Bone Metastasis of Hepatocellular Carcinoma. *J Exp Clin Cancer Res* (2002) 21(3):309–13.

22. Luzzi KJ, MacDonald IC, Schmidt EE, Kerkvliet N, Morris VL, Chambers AF, et al. Multistep Nature of Metastatic Inefficiency: Dormancy of Solitary Cells After Successful Extravasation and Limited Survival of Early Micrometastases. *Am J Pathol* (1998) 153(3):865–73. doi: 10.1016/S0002-9440(10)65682-3

23. Rodríguez-Peralvarez M, Luong TV, Arendrea L, Meyer T, Dhillon AP, Burroughs AK. A Systematic Review of Microvascular Invasion in Hepatocellular Carcinoma: Diagnostic and Prognostic Variability. *Ann Surg Oncol* (2013) 20(1):325–39. doi: 10.1245/s10434-012-2513-1

24. Amado V, González-Rubio S, Zamora J, Alejandre R, Espejo-Cruz ML, Linares C, et al. Clearance of Circulating Tumor Cells in Patients With Hepatocellular Carcinoma Undergoing Surgical Resection or Liver Transplantation. *Cancers* (Basel) (2022) 14(7):1816. doi: 10.3390/cancers14071816

25. Batson OV. The Function of the Vertebral Veins and Their Role in the Spread of Metastases. *Ann Surg* (1940) 112(1):138–49. doi: 10.1097/00000658-194007000-00016

26. Wang X, Lan H, Shen T, Gu P, Guo F, Lin X, et al. Perineural Invasion: A Potential Reason of Hepatocellular Carcinoma Bone Metastasis. *Int J Clin Exp Med* (2015) 8(4):5839–46.

27. Amado V, Gonzalez-Rubio S, Zamora J, Alejandre R, Espejo-Cruz ML, Linares C, et al. Automatically Extracted Machine Learning Features From Preoperative CT to Early Predict Microvascular Invasion in HCC: The Role of the Zone of Transition (ZOT). *Cancers* (Basel) (2022) 13(10):2476. doi: 10.3390/cancers13102476

28. Yu JJ, Xiao W, Dong SL, Liang HF, Zhang ZW, Zhang BX, et al. Clinical Outcome and Prognostic Factors in Hepatocellular Carcinoma Patients With Bone Metastases Medicated With Zoledronic Acid. *Hepatol* (2017) 47(10):1053–60. doi: 10.10111/hepr.12844

29. Zhang L, Niu H, Yang P, Ma J, Yuan BY, Zeng ZC, et al. Serum Lnc34a is a Potential Prediction Biomarker for Bone Metastasis in Hepatocellular Carcinoma Patients. *BMC Cancer* (2021) 21(1):161. doi: 10.1186/s12885-021-07088-6

30. Zhang Y, Xu Y, Ma W, Wu H, Xu G, Chekhonin VP, et al. The Homogeneity and Heterogeneity of Occurrence, Characteristics, and Prognosis in Hepatocellular Carcinoma Patients With Synchronous and Metachronous Bone Metastasis. *J Cancer* (2022) 13(2):393–400. doi: 10.7150/jca.65308

31. Krakham NL, Zavyalova MV, Denisov EV, Vorushin SV, Perelmuter VM. Cancer Invasion: Patterns and Mechanisms. *Acta Naturae*. (2015) 7(2):17–28. doi: 10.32607/20758251-2015-7-2-17-28

32. Zheng Y, Zhou H, Dunstan CR, Sutherland RL, Seibel MJ, The Role of the Bone Microenvironment in Skeletal Metastasis. *J Bone Oncol* (2013) 2(1):47–57. doi: 10.1016/j.jbo.2012.11.002

33. Liu H, Pan Z, Li A, Fu S, Lei Y, Sun H, et al. Roles of Chemokine Receptor 4 (CXCR4) and Chemokine Ligand 12 (CCL12) in Metastasis of Hepatocellular Carcinoma Cells. *Cell Mol Immunol* (2008) 5(3):373–8. doi: 10.1038/cmi.2008.46

34. Roodman GD. Mechanisms of Bone Metastasis. *N Engl J Med* (2004) 350(16):1655–64. doi: 10.1056/NEJMra030831

35. Mundy GR. Metastasis to Bone: Causes, Consequences and Therapeutic Opportunities. *Nat Rev Cancer* (2002) 2(8):584–93. doi: 10.1038/nrc867

36. Santini D, Pantano F, Riccardi F, Di Costanzo GG, Addeo R, Guida FM, et al. Natural History of Malignant Bone Disease in Hepatocellular Carcinoma: Final Results of a Multicenter Bone Metastasis Survey. *PloS One* (2014) 9(8): e105268. doi: 10.1371/journal.pone.0105268

37. Taki Y, Yamaoka Y, Takayasu T, Ino K, Shimahara Y, Mori K, et al. Bone Metastases of Hepatocellular Carcinoma After Liver Resection. *J Surg Oncol* (1992) 50(12):1–8. doi: 10.1002/jso.2930500104

38. Hirai T, Shinoda Y, Tateishi R, Asaoka Y, Uchino K, Wake T, et al. Early Detection of Bone Metastases of Hepatocellular Carcinoma Reduces Bone Fracture and Paralysis. *Ipn J Clin Oncol* (2019) 49(6):529–36. doi: 10.1093/jco/ohy028

39. Lu Y, Hu JG, Lin XJ, Li XG. Bone Metastases From Hepatocellular Carcinoma: Clinical Features and Prognostic Factors. *Hepatobiliary Pancreat Dis Int* (2017) 16(5):499–505. doi: 10.1016/S1440-3827(16)00173-X

40. Boyle WJ, Simonet WS, Lacey DL. Osteoclast Differentiation and Activation. *Nature* (2003) 423(6937):337–42. doi: 10.1038/nature01658

41. Udagawa N, Koide M, Nakamura M, Nakamichi Y, Yamashita T, Uehara S, et al. Osteoclast Differentiation by RANKL and OPG Signaling
58. Soysa NS, Alles N. NF-κB Functions in Osteoclasts. Biochem Biophys Res Commun (2009) 378(1):1–5. doi: 10.1016/j.bbrc.2008.10.146

59. Hofbauer LC, Schoppe M. Clinical Implications of the Osteoprotegerin/RANKL/RANK System for Bone and Vascular Diseases. JAMA (2004) 292(4):490–9. doi: 10.1001/jama.292.4.490

60. Huang L, Cheng YY, Chow LT, Zheng MH, Kumta SM. Tumour Cells Produce Receptor Activator of NF-κB Ligand (RANKL) in Skeletal Metastases. J Clin Pathol (2002) 55(11):877–8. doi: 10.11138/jcp.55.11.877

61. Sasaki A, Ishikawa K, Haraguchi N, Inoue H, Ishio T, Shibata K, et al. Receptor Activator of Nuclear factor-kappaB Ligand (RANKL) Expression in Hepatocellular Carcinoma With Bone Metastasis. Ann Surg Oncol (2007) 14(3):1191–9. doi: 10.1245/s10434-006-0977-4

62. Bhatia P, Sanders MM, Hansen MF. Expression of Receptor Activator of Nuclear factor-kappaB is Inversely Correlated With Metastatic Phenotype in Breast Carcinoma. Clin Cancer Res (2005) 11(1):162–5.

63. Bouizar Z, Spyratos F, Deytieux S, de Vernejoul MC, Jullienne A. Polymerase Chain Reaction Analysis of Parathyroid Hormone-Related Protein Gene Expression in Breast Cancer Patients and Occurrence of Bone Metastases. Cancer Res (1993) 53(21):5076–8.

64. Truong NU, de BEMD, Papavasiliou V, Goltzman D, Kremer R. Parathyroid Hormone-Related Peptide and Survival of Patients With Cancer and Hypercalcaemia. Am J Med (2003) 115(2):115–21. doi: 10.1016/S0002-9343(03)00310-3

65. Roskams T, Willems M, Campos RV, Drucker DJ, Yap SH, Desmet VJ. Parathyroid Hormone-Related Peptide Expression in Primary and Metastatic Liver Tumours. Histopathology (1993) 23(6):519–25. doi: 10.1111/j.1365-2559.1993.tb01237.x

66. Donovan PJ, Achong N, Griffin K, Galligan J, Pretorius CJ, McLeod DS. PTTH-P-Mediated Hypercalcemia: Causes and Survival in 138 Patients. J Clin Endocrinol Metab (2015) 100(5):2024–9. doi: 10.1210/jc.2014-4250

67. Jin J, Chung JO, Chung MY, Cho DH, Chung DJ. Clinical Characteristics, Causes and Survival in 115 Cancer Patients With Parathyroid Hormone Related Protein-Mediated Hypercalcemia. J Bone Metab (2017) 24(4):249–55. doi: 10.11005/jbm.2017.24.4.249

68. Zhang S, Xu Y, Xie C, Ren L, Wu G, Yang M, et al. RNF219/α-Catenin/βCatenin Axis Promotes Hepatocellular Carcinoma Bone Metastasis and Associated Skeletal Complications. Adv Sci (Weinh). (2021) 8(4):2001961. doi: 10.1002/advs.202001961

69. Huang Z, Chu L, Liang J, Tan X, Wang Y, Wen J, et al. H19 Promotes HCC Bone Metastasis Through Reducing Osteoprotegerin Expression in a Protein Phosphatase 1 Catalytic Subunit Alpha/p38 Mitogen-Activated Protein Kinase-Dependent Manner and Sponging microRNA 200b-3p. Hepatology (2021) 74(1):214–32. doi: 10.1002/hep.31673

70. Ma ZJ, Wang Y, Li HF, Liu MH, Bi FR, Ma L, et al. LncZEB1-AS1 Regulates Hepatocellular Carcinoma Bone Metastasis via Regulation of the miR-302b-EGFR-PI3K-AKT Axis. J Cancer. (2020) 11(17):5118–28. doi: 10.7150/jca.45995

71. Zhang L, Niu H, Ma J, Yuan BY, Chen YH, Zhuang Y, et al. The Molecular Mechanism of LncRNA34a-Mediated Regulation of Bone Metastasis in Hepatocellular Carcinoma. Mol Cancer. (2019) 18(1):120. doi: 10.1186/s12943-019-1044-9

72. Jin K, Lan H, Wang X, Lv J. Genetic Heterogeneity in Hepatocellular Carcinoma and Paired Bone Metastasis Revealed by Next-Generation Sequencing. Int J Clin Exp Pathol (2017) 10(10):10495–504.

73. Capone E, Iacobelli S, Sala G. Role of Galectin 3 Binding Protein in Cancer Progression: A Potential Novel Therapeutic Target. J Transl Med (2021) 19(1):405. doi: 10.1186/s12967-021-03083-w

74. Dong J, Lin F, Wu W, Liu Y, Huang W. Verteoporfin Inhibits YAP-Induced Bladder Cancer Cell Growth and Invasion via Hippo Signalling Pathway. Int J Med Sci (2018) 15(6):645–52. doi: 10.7150/jims.23460

75. Peng WX, Koirala P, Mo YY. LncRNA-Mediated Regulation of Cell Signaling in Cancer. Oncogene (2017) 36(41):5661–7. doi: 10.1038/onc.2017.184

76. Liu SJ, Dang HX, Lim DA, Feng FY, Maher CA. Long Noncoding RNAs in Cancer Metastasis. Nat Rev Cancer. (2021) 21(7):446–60. doi: 10.1038/s41568-021-00353-1

77. Li T, Xie J, Shen C, Cheng D, Shi Y, Wu Z, et al. Upregulation of Long Noncoding RNA ZEB1-AS1 Promotes Tumor Metastasis and Predicts Poor Prognosis in Hepatocellular Carcinoma. Oncogene (2016) 35(12):1575–84. doi: 10.1038/onc.2015.223

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Yuan, Zhuang, Zhu, Cheng, Liu, Sun, Qiu, Lu and Sartorius. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.